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ABSTRACT
Cancer-Testis antigens (CTA) are immunogenic molecules with normal tissue 
expression restricted to testes but with aberrant expression in up to 30% of non-
small cell lung cancers (NSCLCs). Regulation of CTA expression is mediated in part 
through promoter DNA methylation. Recently, immunotherapy has altered treatment 
paradigms in NSCLC. Given its immunogenicity and ability to be re-expressed through 
demethylation, NY-ESO-1 promoter methylation, protein expression and its association 
with programmed death receptor ligand-1 (PD-L1) expression and clinicopathological 
features were investigated. Lung cancer cell line demethylation resulting from 5-Aza-2′-
deoxycytidine treatment was associated with both NY-ESO-1 and PD-L1 re-expression 
in vitro but not increased chemosensitivity. NY-ESO-1 hypomethylation was observed 
in 15/94 (16%) of patient samples and associated with positive protein expression 
(P < 0.0001). In contrast, PD-L1 expression was observed in 50/91 (55%) but strong 
expression in only 12/91 (13%) cases. There was no association between NY-ESO-1 and 
PD-L1 expression, despite resultant re-expression of both by 5-Aza-2′-deoxycytidine. 
Importantly, NY-ESO-1 hypomethylation was found to be an independent marker of 
poor prognosis in patients not treated with chemotherapy (HR 3.59, P = 0.003) in 
multivariate analysis. In patients treated with chemotherapy there were no differences 
in survival associated with NY-ESO-1 hypomethylation. Collectively, these results 
provided supporting evidence for the potential use of NY-ESO-1 hypomethylation as a 
prognostic biomarker in stage 3 NSCLCs. In addition, these data highlight the potential 
to incorporate demethylating agents to enhance immune activation, in tumours 
currently devoid of immune infiltrates and expression of immune checkpoint genes.
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INTRODUCTION
Lung cancer accounts for most cancer deaths 
worldwide, with the incidence in the developing world set to 
rise [1]. While immune checkpoint therapy has already altered 
treatment paradigms [2–4], lung cancer immunotherapy 
using vaccination strategies and immunomodulatory agents 
[5] have largely yielded disappointing results [6]. Responses 
to single agent Programmed Death 1 (PD-1) and its ligand 
PD-L1 are modest [~24%] and combination strategies with 
chemotherapy and other immunotherapies are the subject of 
active study [7].
One group of potential targets are the cancer-testis 
antigens (CTA or CT antigens), which are exclusively 
expressed in normal testes and placenta but also aberrantly 
expressed in some tumours. New York-Esophageal-1 (NY-
ESO-1), is a CTA whose expression occurs in several 
cancers including ~30% lung cancers [8, 9], as well as in 
ovarian, head and neck cancers, melanoma, sarcomas and 
neuroblastoma [10]. These antigens are attractive because 
they are not expressed in somatic tissues and therefore 
can be used as targets for vaccination and adoptive T cell 
transfer [11, 12].
There is increasing evidence supporting the role of 
epigenetic aberrations in early malignant transformation, 
raising the possibility of identifying novel epigenetic-
related chemopreventive strategies or reliable diagnostic 
tools using epigenetic biomarkers [13]. Promoter DNA 
methylation is a covalent chemical modification resulting 
in the addition of a methyl group to the carbon-5-position 
of cytosine (C) residues that are followed immediately by 
guanine (G). It has gained recognition as a key molecular 
mechanism in the regulation of both oncogenes and 
tumour suppressors. A number of recent reports have 
indicated that promoter methylation plays a critical role in 
ensuring that CT antigens located on the X chromosome 
[10] (CT-X, which accounts of half of all known CT 
antigens) are silenced in somatic tissues. Demethylating 
agents such as 5-Aza-2′-deoxycytidine (5-Aza-dC) 
have been shown to induce type-1 interferon pathways 
and to upregulate CTA expression [14], suggesting that 
concomitant program death-1 (PD-1) pathway inhibition 
may enhance the immune effects of epigenetic modulators 
on T cells. 
We recently reported that NY-ESO-1 protein 
expression was associated with poorer survival in lung 
cancer patients but yet increased benefit in patients 
undergoing cisplatin-based chemotherapy [15]. Herein, we 
sought to determine whether NY-ESO-1 expression was 
regulated by promoter methylation in lung tumours, and if 
so, whether methylation status can be used as a predictive 
and/or prognostic marker in NSCLC. Furthermore, we 
investigated whether promoter demethylation using, 
5-Aza-dC, a DNA methyltransferase inhibitor, influenced 
the chemosensitivity of lung cancer cell lines in vitro. 
Lastly, we investigated the effects of demethylation on 
PD-L1 expression in vitro and correlated expression of 
PD-L1 with NY-ESO-1 expression and methylation in 
patients with stage 3 NSCLC.
RESULTS 
NY-ESO-1 promoter is hypermethylated in lung 
cancer cell lines and the methylation level is 
predictive of NY-ESO-1 mRNA and protein levels
We determined the NY-ESO-1 promoter methylation 
status in 14 lung cancer cell lines. Variable levels of 
promoter methylation were observed, with 9 out of 14 cell 
lines demonstrating >90% NY-ESO-1 hypermethylation 
(Figure 1A). Three lung cancer cell lines (NCI-2170, 
SK-LC-02, and SK-LC-05) exhibited approximately equal 
proportions of methylated and unmethylated NY-ESO-1 
alleles (40–60% methylation), while two remaining cell 
lines (SK-LC-17 and SK-LC19) exhibited NY-ESO-1 
hypomethylation, <10% methylation (Figure 1A). 
The protein expression level of NY-ESO-1 in all 
14 lung cancer cell lines was subsequently investigated 
using a specific anti-NY-ESO-1 antibody (clone E978) 
by IHC analysis [16] (Figure 1B, 1C). A NY-ESO-1+ve 
melanoma cell line, LM-MEL-53, and a NY-ESO-1–ve 
colorectal cancer cell line, HCT116, were also included 
in the IHC analysis as positive and negative controls [17]. 
Among the lung cancer cell lines, 4 out of 14, (SK-LC-17, 
SK-LC-19, SK-LC-02, and NCI-H2170) stained positive 
for NY-ESO-1 (Figure 1A, Supplementary Figure 3 and 
Supplementary Table 3). The NY-ESO-1+ve lung cancer 
cell lines were found to have completely or partially 
hypomethylated NY-ESO-1 promoters. In contrast, the 
NY-ESO-1-ve lines contained hypermethylated NY-ESO-1 
promoters, with great majority (9/10) displaying more 
than 90% methylation (Figure 1A). The mean promoter 
methylation level was significantly higher (P < 0.001, 
Student’s t-test) in the NY-ESO-1-ve cell lines, as compared 
to NY-ESO-1+ve cell lines (Figure 1B). Importantly, NY-
ESO-1 promoter methylation status negatively correlated 
with NY-ESO-1 mRNA expression (Pearson’s correlation, 
r = –0.8992, P < 0.0001) (Figure 1D). Together, these data 
confirm a significant inverse correlation between NY-
ESO-1 promoter methylation and NY-ESO-1 expression 
at both the mRNA and protein levels in lung cancer cell 
lines.
5-Aza-2’-deoxycytidine treatment induces  
NY-ESO-1 and PD-L1 re-expression in  
NY-ESO-1 methylated lung cancer cell lines
Next, we treated a panel of 10 NY-ESO-1-ve cell 
lines (9 of which showed > 90% NY-ESO-1 methylation) 
with the demethylating agent 5-Aza-2’-deoxycytidine 
(5-Aza-dC) for 3 days. The NY-ESO-1 hypomethylated 
cell lines SK-LC-17 and SK-LC-19 were also treated 
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as additional controls. 5-Aza-dC treatment resulted in a 
significant reduction of NY-ESO-1 promoter methylation 
and consequential increased mRNA expression in A549 
and NCI-H460 cells (Figure 2A, 2B), but not in SK-LC-17 
and SK-LC-19 at similar doses (Supplementary Figures 
4 and 5, NY-ESO-1 mRNA expression was already high 
prior to 5-Aza-dC treatment). In the 10 NY-ESO-1-ve 
cell lines, treatment resulted in strong IHC expression 
of NY-ESO-1 in three and patchy positivity in a further 
three cell lines (Figure 2C, Supplementary Table 3 and 
Supplementary Figure 6). 
Similarly, de novo PD-L1 expression was observed 
in 2/10 cell lines, but on exposure to 5-Aza-dC the positive 
cell lines remained positive but a further six (out of eight) 
previously negative cell lines became positive. There 
was no association between PD-L1 re-expression and 
NY-ESO-1 re-expression (Supplementary Table 3 and 
Supplementary Figure 7). 
NY-ESO-1 promoter hypomethylation is a 
prognostic marker in NSCLC
To investigate whether the promoter methylation 
status of NY-ESO-1 can serve as a prognostic marker, 
we performed qMS-PCR analysis in a cohort of 99 
NSCLC tumours using DNA extracted from FFPE blocks. 
Matching NY-ESO-1 expression was determined by IHC 
analysis in these tumours (Figure 3A and Supplementary 
Figure 8). qMS-PCR analysis was unsuccessful for 
5 tumour specimens due to the poor quality of DNA 
obtained from FFPE samples. 64/68 (94%) NY-ESO-
1-ve tumours were hypermethylated, while 11/26 (42%) 
NY-ESO-1+ve tumours were hypomethylated (Figure 
3A and Supplementary Figure 8). Importantly, a 
significant association between NY-ESO-1 promoter 
hypomethylation and NY-ESO-1 protein expression (P 
< 0.0001) was found in this lung cancer cohort (Figure 
Figure 1: NY-ESO-1 promoter methylation correlated with NY-ESO-1 mRNA and protein expression in lung cancer 
cell lines. (A) Bar graph showing the results obtained from qMS-PCR analysis in a panel of 14 lung cancer cell lines. Red bars indicate 
cell lines stained positive for NY-ESO-1 expression by immunohistochemistry. Data shown are mean % methylation with SD (from 3 or 
more independent experiments). (B) The mean NY-ESO-1 methylation level (% methylation) in NY-ESO-1+ve lung cancer cell lines are 
significantly lower (i.e. hypomethylated) than NY-ESO-1 negative lung cancer cell lines (P < 0.001, Student’s t-test). Error bars represent 
SEM. (C) Representative IHC images for NY-ESO-1 using specific anti-NY-ESO-1 antibody (E978) in (i) testis, positive control; (ii) 
normal lung tissue without primary E978 antibody, negative control; (iii) lung cancer cell line SK-LC-17 and (iv) lung cancer cell line 
A549. (D) Non-linear regression analysis (Pearson correlation, r = –0.8992, P < 0.0001) for NY-ESO-1 mRNA expression and promoter 
DNA methylation (% methylation) in 14 lung cancer cell lines. Cell lines showed positive or negative IHC staining for NY-ESO-1 protein 
expression were indicated by red and black circles, respectively.
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3B, 3C). There were no associations between NY-ESO-1 
promoter hypomethylation and clinicopathological 
features, such as the presence of specific oncogenic 
mutations, tumour histology or stage (Table 1). Despite 
not reaching statistical significance, there is a larger 
number of adenocarcinoma exhibiting NY-ESO-1 
promoter hypermethylation, when compared to that of 
squamous cell carcinoma. No significant association was 
found between PD-L1 positivity and NY-ESO-1 promoter 
methylation status or NY-ESO-1 expression (Figure 3C).
To determine whether NY-ESO-1 promoter 
hypermethylation is prognostic and/or predictive of lung 
cancer patient survival or response to chemotherapy, 
univariate Cox regression analysis was performed and 
demonstrated a significant association with poorer survival 
(HR 2.52, 95% CI: 1.14 – 5.58, P = 0.022) in tumours 
with low NY-ESO-1 methylation when no adjuvant 
chemotherapy was used (Figure 4A and Supplementary 
Table 4). In the patient group that received adjuvant 
chemotherapy, no significant difference in overall 
survival was observed (Figure 4B and Supplementary 
Table 4). These results were similar to the outcome of 
a univariate Cox regression analysis performed to test 
the prognostic value of NY-ESO-1 protein expression 
as a marker for survival (HR 2.16, 95% CI: 1.13 – 4.09, 
P = 0.019)  (Supplementary Table 5) [15]. In multivariate 
Cox regression analysis adjusting for stage, histology 
and chemotherapy NY-ESO-1 hypomethylation was 
an independent poor prognostic marker (HR 3.59, 95% 
CI: 1.56 – 8.26, P = 0.003), whereas treatment with 
chemotherapy and NY-ESO-1 hypomethylation was 
an independent predictor of improved survival (HR 
0.211, 95% CI: 0.046 – 0.973, P = 0.046) (Figure 4C, 
Supplementary Table 6). Despite the poorer prognosis 
of patients with hypomethylated NY-ESO-1 promoter, 
these findings suggest that this patient subset may in 
fact respond better to cisplatin-based chemotherapy. 
Collectively, these results highlighted the potential use 
of NY-ESO-1 promoter methylation as both a prognostic 
biomarker of outcome, as well as a predictive biomarker 
of chemoresponse.
Effect of NY-ESO-1 on chemosensitivity to cisplatin 
To further investigate the link between NY-ESO-1 
methylation status and cisplatin response, we performed 
MTS assays to determine the GI50 for cisplatin in the 14 
lung cancer cell line panel. The GI50 for cisplatin was 
Figure 2: Treatment of lung cancer cells with demethylating agent, 5-Aza-dC, results in the demethylation of the NY-
ESO-1 promoter and consequential mRNA and protein re-expression. NY-ESO-1 hypermethylated lung cancer cell lines A549 
and NCI-H460 were treated with or without 5-Aza-dC for 72 hr at the indicated doses. Results obtained from (A) qMS-PCR (N = 3, mean 
with SD), (B) qRT-PCR (N = 2, mean with SD, perform in triplicates) or (C) IHC analysis (representative image) were shown. 
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significantly lower (P = 0.043) in NY-ESO-1+ve lines 
(40.1 ± 7.6 µM) compared to NY-ESO-1-ve cell lines 
(102.9 ± 14.6 µM) (Supplementary Figure 9A, 9B). 
Consistent with this, a significant positive correlation 
between NY-ESO-1 expression and cisplatin sensitivity 
was observed (Supplementary Figure 9C, 9D). 
Given the increased sensitivity to cisplatin in NY-
ESO-1 positive cell lines, we investigated whether 5-Aza-
dC-induced re-expression of NY-ESO-1 could enhance 
sensitivity to cisplatin in NY-ESO-1-ve, hypermethylated 
cell lines. Two cisplatin resistant hypermethylated 
cell lines A549 and NCI-H460 were used. NY-ESO-1 
hypomethylation and re-expression at both mRNA and 
protein level was robustly induced by 5-Aza-dC treatment. 
However, there was no significant change in sensitivity 
to cisplatin following 5-Aza-dC treatment in both A549 
and NCI-H460 (Supplementary Figures 4, 10A, 10B). 
To confirm these findings, we also performed siRNA-
mediated knockdown of NY-ESO-1 in the NY-ESO-
1+ve SK-LC-17 and SK-LC-19 cells, followed by MTS 
assays. Transient transfection with NY-ESO-1 targeting 
siRNAs resulted in > 80% knockdown of NY-ESO-1 
expression in both cell lines (Supplementary Figure 
10C, 10D). However, no significant change in cisplatin-
induced growth inhibition was observed after NY-ESO-1 
knockdown (Supplementary Figure 10E, 10F). These 
results suggest that NY-ESO-1 does not play a functional 
role in mediating in vitro cisplatin-related chemo-
sensitivity in lung cancer cell lines. 
DISCUSSION
We have demonstrated that NY-ESO-1 
hypomethylation frequently occurs in lung cancer cell lines 
and tissue specimens and the relative level of methylation 
significantly correlated with both NY-ESO-1 mRNA and 
protein expression. NY-ESO-1 hypomethylation was an 
independent adverse prognostic marker in patients with 
NSCLC and demethylation of the NY-ESO-1 promoter 
was associated with re-expression of NY-ESO-1. Despite 
the association of NY-ESO-1 hypermethylation and 
consequential protein expression with chemosensitivity in 
Figure 3: NY-ESO-1 promoter methylation correlated with NY-ESO-1 protein expression in lung cancer patient 
samples. (A) NY-ESO-1 promoter methylation in 94 human FFPE lung cancer samples, grouped into NY-ESO-1 negative and positive 
cohorts. (B) Significant differential methylation (P < 0.001, Student’s t-test) was observed between NY-ESO-1 positive and negative 
groups. Error bars represent SD. (C) NY-ESO-1 promoter hypomethylation was associated with NY-ESO-1 protein expression, while NY-
ESO-1 hypermethylation was associated with lack of detectable NY-ESO-1 expression in IHC analysis. A significant association between 
NY-ESO-1 hypomethylation and protein expression was found, as determined by Fisher’s exact test (P < 0.0001). No associated between 
PD-L1 expression and NY-ESO-1 expression or methylation was observed.
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patient samples, chemosensitivity of lung cancer cell lines 
to cisplatin treatment was unaffected by either 5-Aza-
dC-induced promoter demethylation (and associated re-
expression of NY-ESO-1) or siRNA-mediated knockdown 
of NY-ESO-1 in vitro. These results indicate that unknown 
extrinsic factors are present in patients (but absent in cell 
lines) that mediate chemosensitivity to cisplatin. One 
such factor could be the innate immune system and the 
associated cellular components. Alternatively, NY-ESO-1 
is a non-functional surrogate marker for chemoresponse. 
Lastly, we did not demonstrate an association between 
PD-L1 expression and NY-ESO-1 methylation however 
of considerable interest was the finding that 5-Aza-dC 
induces not just NY-ESO-1 expression but also PD-L1 
expression in a significant number of NSCLC cell lines.
These data are consistent with previous reports 
[8, 18], demonstrating that NY-ESO-1 hypomethylation 
and resulting protein expression is a poor prognostic 
marker in NSCLC. The use of quantitative MS-PCR 
technology enables the robust detection of gene-specific 
methylation with the need for only small quantities 
of tissues from patients. Comparing to the traditional 
standard-of-care molecular pathology tools such as 
the IHC, the MS-PCR approach enable a more precise 
quantitative measurements for comprehensive statistical 
analysis (i.e. the regression analysis to determine the 
predictive power of potential biomarkers). Indeed, in our 
current study, we have demonstrated that the NY-ESO-1 
methylation status can be used to accurately predict NY-
ESO-1 expression in patient specimens. Clearly, when 
tissue samples are limited, this approach may represent 
a very useful assay for candidate gene markers that are 
regulated by promoter methylation at the transcriptional 
level.
Despite not reaching statistical significance, there 
is a larger number of adenocarcinoma (ADC) exhibiting 
NY-ESO-1 promoter hypermethylation when compared to 
that of squamous cell carcinoma (SCC). Given promoter 
hypermethylation leads to epigenetic silencing, it is 
therefore predicted that a larger proportion of SCC would 
be NY-ESO-1 positive when compared to ADC. In fact, 
this prediction held true based on the findings made in our 
prior study [15] and is in close agreement to what was 
previously reported in several independent lung cancer 
patient cohorts [8, 9, 18–20]. Interestingly, SCC is not 
only more likely to express NY-ESO-1 but also appears 
to respond better to immunotherapy, regardless of PD-L1 
expression [21, 22].
While the negative association of CTA expression 
and patient survival has been consistently reported [8, 
15, 18], the biological explanation for these observations 
remains elusive. However, the co-expression of these 
CTAs hinted at the possibility that these phenomena 
were part of a global demethylation event, which leads 
to not only aberrant expression of CTAs but also other 
oncogenes. Clearly, CTA expression is associated with 
more advanced disease stages, perhaps reflecting more 
widespread epigenetic alterations as cancer progresses. 
Table 1: Clinicopathological features associated with NY-ESO-1 promoter methylation in stage 3 
NSCLC patients
Variables NY-ESO-1 Low Meth N = 14 n (%)
NY-ESO-1 High Meth  
N = 80 n (%) P-value
Age, mean (range) years 63.1 (46.2 – 85.6) 64.4 (29.0 – 81.4) 0.656
Male 9 (64) 43 (54) 0.566
Smoker/Ex-Smoker 14 (100) 66 (83) 0.119
Histology
    Adenocarcinoma
    Squamous
    Other
4 (29)
5 (36)
5 (36)
47 (59)
22 (28)
11 (14)
0.059
Mutations
    TP53
    KRAS
    EGFR
    PIK3CA
    MET
2 (14)
2 (14)
0 (0)
1 (7)
0 (0)
5 (6)
16 (20)
12 (15)
6 (8)
3 (4)
0.291
0.616
0.121
0.963
0.462
NY-ESO-1
    IHC +ve
    IHC -ve
11 (79)
3 (21)
15 (19)
65 (81)
< 0.0001
Overall survival, mean (range) months
    All patients
    Adjuvant chemotherapy
    No chemotherapy
14.8 (0.6 – 37.5)
22.2 (9.4 – 37.5)
9.3 (0.6 – 35)
29.1 (0.03 – 146.5)
28.5 (0.60 – 117.1)
29.6 (0.03 – 146.5)
0.003
0.149
0.004
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The immunogenicity of these proteins may have 
functional relevance given the recent excitement with 
immune checkpoint inhibitors [11]. Although we did not 
find a significant association between NY-ESO-1 and 
PD-L1 expression, the induced expression of PD-L1 in 
negative cell lines by 5-Aza-dC treatment, suggests that 
global demethylation may trigger aberrant expression of 
immunological markers such as PD-L1 in vitro.
Utilizing NY-ESO-1 or demethylating agents as 
a combination strategy with checkpoint inhibition in 
NSCLC, may still hold promise. NY-ESO-1 is one of the 
most immunogenic CTAs, making it an attractive target for 
cancer vaccines [10]. It has been used as a tumour vaccine 
in a variety of tumour types, in particular in melanoma 
[23–25] with effective T-cell responses post vaccination, 
albeit without significant clinical improvement in the 
disease. Combination approaches may offer another 
mechanisms, by which the immunoregulatory brakes are 
removed while also activating tumour specific T-cells. 
Certainly, the clinical effect of T-cell activation has been 
effectively demonstrated using adoptive T-cells stimulated 
towards NY-ESO-1 epitopes [26].
The fact that de novo but not induced NY-ESO-1 
expression modulates chemosensitivity is worthy of 
further investigation. We had previously postulated 
that the survival differences associated with patients 
Figure 4: Clinical correlations of NY-ESO-1 promoter methylation and overall survival in patients underwent surgery 
alone or surgery and adjuvant chemotherapy. Survival curves of patients with high versus low NY-ESO-1 methylation were 
compared using the log-rank Mantel-Cox test. (A) A significant trend (P = 0.022) was observed in the patients not receiving adjuvant 
chemotherapy, where patients with NY-ESO-1 low methylation showed worse overall survival. (B) However, in the patient group that 
was treated with chemotherapy, no difference in overall survival was observed between patients with high or low NY- ESO-1 promoter 
methylation. (C) Forest plot and a summary table detailing the clinicopathological features that are associated with overall survival of the 
patient cohort in a multivariate analysis. SQ, Squamous Cell carcinoma; ADC,  Adenocarcinoma; AdjChemo,  Adjuvant Chemotherapy.
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undergoing chemotherapy who were NY-ESO-1 positive 
may have been mediated by an immune response to 
treatment [15]. Certainly, the immunogenicity of CTAs 
has previously been demonstrated and that the effect of 
tumor lysis as an immune primer is feasible. However, our 
results indicate that lung cancer cell lines expressing NY-
ESO-1 are more sensitive to chemotherapy, even in the 
absence of an intact immune system. Additionally, our in 
vitro data suggests that NY-ESO-1 itself does not play a 
direct functional role in determining chemosensitivity, as 
both 5-Aza-dC-induced re-expression or RNAi-mediated 
knockdown of NY-ESO-1 failed to alter chemosensitivity. 
However, it should be noted that the sample size used in 
determining the association of in vitro chemosensitivity 
and NY-ESO-1 protein expression is small. Therefore, 
experimental results from a larger panel of lung cancer 
cell lines are required before a solid conclusion could be 
made in this regard.
There are several potential explanations for our 
findings. First, tumours that express NY-ESO-1 have 
undergone extensive epigenetic reprogramming resulting 
in the coordinated re-expression of many other genes that 
alter chemosensitivity [27]. However, the level of NY-
ESO-1 re-expression in vitro appears to be significantly 
lower when compared to cell lines with de novo NY-
ESO-1 expression. 5-Aza-dC is cytotoxic agent in vitro 
and it is possible that our assay failed to detect robust 
changes in chemosensitivity due to inadequate NY-
ESO-1 re-expression. In part, this could be improved with 
multiple, continual low dose exposure to 5-Aza-dC or 
combining 5-Aza-dC with a clinical histone deacetylase 
inhibitor such as Vorinostat to further enhance NY-
ESO-1 expression to investigate its role in regulating 
chemosensitivity.
Our cell line data demonstrated robust NY-ESO-1 
promoter demethylation and consequential induction of 
NY-ESO-1 mRNA expression when tumour cells were 
treated with 25–100 nM 5-Aza-dC for a continuous period 
of 3 days. Unlike other previous studies [9, 28, 29], we 
have also demonstrated re-expression of NY-ESO-1 at the 
protein level. However, with the exception of NCI-H520 
which demonstrated re-expression in > 80% of total cell 
population, the re-expression was restricted to < 20–30% 
of the total cell population in majority of the tumour 
cell lines analyzed (e.g. NCI-H460, A549, NCI-H838, 
NCI-H522 and SK-LC-05). It is currently unknown as 
to why 5-Aza-dC-mediated NY-ESO-1 re-expression at 
protein level was not observed in majority of the total 
cell population. However, one possible explanation 
is that the observation is likely to reflect a pattern of 
heterogenous promoter methylation of NY-ESO-1 in a 
given cell population. As a result, the concentration of 
5-Aza-dC and the duration of treatment used was only 
sufficient to induce NY-ESO-1 demethylation and protein 
re-expression in cells exhibiting low level of NY-ESO-1 
methylation. By comparison, complete demethylation and 
protein re-expression in cells exhibiting high levels of NY-
ESO-1 methylation is expected to come from treatment 
using 5-Aza-dC at higher doses, with longer duration, 
or in combination with HDAC inhibitors (that acetylate 
histones at the promoters).
Recently, Odunsi and colleagues presented a novel 
immune-chemotherapy approach showing that 5-Aza-
dC increased the effectiveness of an NY-ESO-1 vaccine 
in 12 patients with platinum refractory ovarian cancer 
[30]. Moreover, a small study in NSCLC suggested that 
epigenetic therapy may sensitize cancers to immune 
checkpoint therapy targeting PD-L1/PD-1 interaction 
[31]. Six patients who received treatment on a clinical 
trial of epigenetic therapy were placed on trials for anti 
PD-1 and PD-L1 immunotherapy with three achieving 
durable partial and two stable disease. At the cellular 
level, the mechanism by which epigenetic priming 
of immunotherapy induces improved outcomes may 
involve upregulation of gene clusters associated with 
interferon-signaling, antigen processing, as well as genes 
encoding CTAs [14, 31]. Our findings also suggest that 
PD-L1-ve tumors may become positive through the use 
of demethylating agents. Indeed, 5-Aza-dC treatment 
has previously shown to induce PD-L1 demethylation 
and consequential mRNA and/or protein re-expression 
in the KG1 leukemia cell line, in vitro activated primary 
CD8+ T cells, CD4+ and CD8+ T cells from patients with 
myelodysplastic syndrome and acute myeloid leukemia 
[32–34]. Given 5-Aza-dC-mediated PD-L1 demethylation 
has been reported in these previous studies and that 5-Aza-
dC is a well-established demethylating agent, it is therefore 
unlikely that 5-Aza-dC-mediated PD-L1 re-expression 
occurs independent of PD-L1 promoter demethylation. 
Importantly, the hypothesis of combining epigenetic 
therapy together with immune checkpoint inhibitors may 
shift the balance toward enhanced adaptive and innate 
immune response and is currently being investigated in a 
prospective phase II clinical trial (NCT01928576).
High mutational load and neoantigen expression has 
been shown to predict for responses to immune checkpoint 
inhibition [35]. In this context, it is plausible that global 
demethylation, which frequently occurs in malignancies, 
may result in (re)expression of genes or neo-antigens that 
were previously silenced. This could explain the superior 
responses observed in patients treated with PD-1 inhibitors 
following administration of demethylating agents [31, 36]. 
Clearly, the concept of tumor lysis exposing immunogenic 
proteins and/or neo-antigens remains plausible when 
considering these early data.
The field of immunotherapy is rapidly changing 
and predictors of therapeutic benefit are increasingly 
important. The use of demethylating agents in some 
diseases has shown benefit, but in most solid organ cancers 
it has been largely speculative. It remains to be seen 
whether targeting tumours with a de novo unmethylated 
phenotype with immunological agents may improve 
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outcomes. However, our data suggest that combination 
chemo-immuno therapies may provide an important 
strategy for these tumours, especially given their poorer 
clinical outcomes.
MATERIALS AND METHODS
Patients and specimens
A total of 99 tumour samples were obtained from 
two tertiary hospitals (Austin and St Vincent’s Hospitals, 
Melbourne, Australia) for patients who had been treated for 
pathological N2 (pN2)/stage 3 NSCLC. Medical records 
were retrospectively reviewed for clinicopathological 
characteristics. The resected primary specimens and 
associated nodal tissues were used. Patients were staged 
pre-operatively with positron emission tomography 
(PET) scans or mediastinoscopy. Some of these patients 
were diagnosed prior to the broad acceptance of adjuvant 
chemotherapy resulting in two cohorts: 45 (45.5%) 
patients received four cycles of platinum-based doublet 
chemotherapy and 54 (54.5%) did not. The study was 
approved by the Austin Hospital’s Human Research Ethics 
Committee.  
Cell culture
A panel of 14 lung cancer cell lines were used: 
NCI-H2170, A549, NCI-H522, HCC 827, NCI-H460, 
NCI-H520, NCI-H1975, and NCI-H1650, were purchased 
from American Type Culture Collection (ATCC), while 
SK-LC-02, SK-LC-05, SL-LC-15, SK-LC-17, and 
SK-LC-19, were provided by Prof. Gerd Ritter at the 
Memorial Sloan-Kettering, and NCI-H838 by Prof. Neil 
Watkins from Monash Institute of Medical Research, 
Australia (Supplementary Table 1). All cell lines have 
been tested and authenticated using GenePrint®10 System 
(Promega, USA). Cells were grown in a recommended 
medium culture in a humidified incubator with 5% CO2 
at 37°C. 
Immunohistochemistry
Protein expression of NY-ESO-1 was determined 
by immunohistochemistry (IHC) analysis on formalin-
fixed paraffin embedded (FFPE) tissues [15] and tissue 
culture tumour cell lines [37] as previously described. 
Briefly, 4-µm sections were cut and stained with the 
murine monoclonal anti-NY-ESO-1 antibody (clone E978) 
obtained from the Ludwig Institute for Cancer Research 
and used at a final concentration of 2.5 µg/mL. PD-L1 
positivity was defined as > 5% cells with membranous 
staining of intensity and strong positivity was defined 
as > 50% cells with membranous staining of intensity. 
Testicular tissue sections were used as positive controls. 
Normal lung tissues and absence of primary antibodies 
were used as negative controls. PD-L1 staining was 
performed using a rabbit monoclonal anti-PD-L1 antibody 
(E11340 XP, Cell Signaling Technology), as previously 
described [38].
Bisulphite treatment
Genomic DNA (gDNA) was isolated from lung 
cancer cell lines and archival FFPE tissues using DNeasy 
Kits (Qiagen), in accordance with the manufacturer’s 
instructions. Bisulfite conversion of the DNA samples 
was performed as previously described [39]. The quantity 
and quality of the gDNA was measured using a NanoDrop 
2000 Spectrophotometer (Thermo Scientific). For bisulfite 
treatment, 1 µg of isolated gDNA was converted using 
the EpiTect Bisulfite Kit (Qiagen), according to the 
manufacturer’s instructions. For subsequent methylation 
analysis, DNA was eluted with RNAase-free water to a 
final concentration of 25 ng/μL.
Quantitative methylation specific-PCR
Primers utilized for quantitative methylation 
specific-PCR (qMS-PCR) were previously described and 
validated [17]. The primer sequences are provided in the 
Supplementary Table 2. The locations of primers relative 
to the CpG island of the NY-ESO-1 (encoded by the 
CTAG1B gene) promoter were determined by webgene 
(http://www.itb.cnr.it/sun/webgene/) using published criteria 
(Supplementary Figure 1A) [40]. Primers targeting the 
converted DNA sequences of beta-actin (ACTB) gene were 
used as normalization controls in MS-PCR reactions [41]. 
PCR reactions were performed as previously described  [42, 
43] and in duplicate in a final volume of 10 μl using 50 ng 
bisulfite-converted DNA with 10 mM forward and reverse 
primers, and 1 μl RNAase-free water. 7500 FAST real time 
cycler (Applied Biosystems) was used with the following 
cycling conditions: 1 cycle of 95 °C for 10 minutes, 50 
cycles of 95°C for 15 seconds and 60 °C for 1 min. 
To determine the relative level of NY-ESO-1 
methylation present in each sample, two different 
methods were used: (1) expressed as the percentage 
of methylation (%M); (2) reported as the ratio of 
methylated (M) to unmethylated (UM) molecules for 
a particular locus, as a Log2 (M/UM) ratio [44]. Both 
methods were based on the use of threshold cycle (CT) 
of the NY-ESO-1 gene and of the internal reference 
gene, beta-actin (ACTB). To determine the relative 
amount of methylated or unmethylated alleles in each 
sample, 2-dCT method was employed, where dCT (M) 
= [CT (NY-ESO-1 methylated) - CT (ACTB)]; and dCT 
(UM) = [CT (NY-ESO-1 unmethylated) - CT (ACTB)]. 
Methylation percentage in the samples were calculated 
by M/(M+UM) x 100, where M is the quantity of 
methylated NY-ESO-1 alleles, and UM is the quantity 
of unmethylated NY-ESO-1 alleles, respectively. In 
comparison, Log2 (M/UM) is calculated by Log2 [2-dCT 
(M) / 2^-dCT (UM)].
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The patient sample population was separated into 
NY-ESO-1 methylation low or high groups. An optimal 
functional cut-off of Log2 fold-difference in M/UM of ≥ 5 
was determined by ROC curve analysis (Supplementary 
Figure 2). Samples that has a Log2 (M/UM) ≥ 5 is 
classified into the NY-ESO-1 ‘High Meth’ group, while 
a Log2 (M/UM) < 5 was classified into NY-ESO-1 ‘Low 
Meth’ group. Importantly, 94% (64/68) of NY-ESO-1 
negative tumours were classified into the group containing 
low methylation (i.e. hypomethylation), demonstrating the 
predictive power and the robustness of the cut-off used. 
Using this selection criterion, 84% of tumour specimens 
(79/94) were classified as NY-ESO-1 ‘methylation high’ 
(i.e. hypermethylated) and 16% (15/94) were classified as 
NY-ESO-1 ‘methylation low’ (i.e. hypomethylated). 
Quantitative RT-PCR
Quantitative RT-PCR (qRT-PCR) was performed as 
previously described [45, 46]. Total RNA was extracted 
from exponentially growing cells using RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions. 
cDNA synthesis was performed using Transcriptor 
First Strand cDNA Synthesis Kit with random hexamer 
(Roche). qRT-PCR was carried out using Power SYBR 
Green PCR Master Mix (Life Technologies) on 7900HT 
Fast Real-Time PCR System (Life Technologies) 
according to the manufacturer’s instructions. cDNA 
equivalent to 10 ng RNA was amplified with 75 nM 
forward and 75 nM reverse primers in 10 µL reaction. 
Dissociation curves were performed to confirm specific 
amplifications without primer dimer formation. Samples 
were also subjected to gel electrophoresis analysis to 
confirm that the PCR products were of expected size. 
Abundance of mRNA expression was determined using 
the comparative CT method and expressed relative to 
ACTB expression.  
RNAi-mediated knockdown 
Transient transfection of lung adenocarcinoma 
cell lines, SK-LC-17 and SK-LC-19, with 10 nM 
of non-targeting control siRNA and specific siRNA 
duplexes targeting NY-ESO-1 (s194368, Ambion by 
Life Technology) was performed using Lipofectamine 
RNAiMAX in 24 well plate format, according to the 
manufacturer’s instructions (Invitrogen, USA). Twenty-
four hours post transfection, cells were collected to test for 
knockdown efficiency and re-seeded into 96 well plates 
for MTS assays. 
Treatment with 5-Aza-2′-deoxycytidine (5-Aza-dC)
~1x106 cells were seeded in T-25 flask and treated 
with 5-Aza-2’-deoxycytidine (Sigma) for 3 consecutive 
days at a concentration of 0.1 µM. Cells were washed with 
1X PBS and incubated with fresh medium for a 72-hour 
recovery period, and subsequently transferred into 96-well 
plates for MTS assays. In parallel, cells were harvested 
for RNA and DNA isolation for qRT-PCR and qMS-PCR, 
respectively.
MTS assays
MTS assays were performed as previously described 
[47] using CellTiter 96 (Promega, Madison, USA). Post 
5-Aza-dC treated or NY-ESO-1 knockdown lung cancer 
cell lines were independently seeded in 96-well plates 
(7500 cells per well) and treated with 0.1 µM to 1 mM 
cisplatin for 72 hours. Changes in relative proliferation 
were estimated by measuring the absorbance at 490 nm in 
a microplate reader.
Statistical analysis 
Fisher’s exact test was used to evaluate the 
association between NY-ESO-1 promoter methylation and 
NY-ESO-1 protein expression. Univariate and multivariate 
Cox proportional hazard ratio modeling analyses were 
performed in R (v3.0.1, survival package v2.37–4) and 
STATA (version 12).  Student’s two-tailed t-test was 
performed in Prism 6 (GraphPad Software Inc). 
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